Chloral Hydrate Dosing
For pediatric sedation, use oral chloral hydrate at 50 mg/kg (maximum 2 g total dose) as the standard approach, though low-dose regimens of 10-25 mg/kg combined with other sedatives are commonly used in dental practice 1.
Pediatric Dosing
Standard Sedation Protocol
- Oral route: 50 mg/kg is the most commonly studied and effective dose 2
- Maximum single dose: 2 g total 3
- High-dose range: 80-100 mg/kg (maximum 2 g) has been used safely for CT sedation with 93% success rate 3
- Low-dose dental sedation: 10-25 mg/kg when combined with other sedating medications 1
- Rectal administration: 50 mg/kg shows 84% success rate with lower vomiting risk compared to oral route 2
Onset and Duration
- Sedation onset: 20-60 minutes after administration 4
- Duration: Typically allows completion of procedures without prolonged sedation beyond 2 hours at appropriate doses 3
- Half-life of active metabolite (trichloroethanol): 8-12 hours 4
Adult Dosing
The FDA-approved dosing is limited and appears to reference sublingual formulations rather than the traditional oral liquid 5. However, based on toxicology literature:
- Therapeutic range: 0.5-2 g per day, taken with meals to prevent gastric irritation 4
- Toxic threshold: Doses >1.5-2.0 g can produce symptoms; death reported at ~10 g (some cases at 5 g) 4, 6
Critical Safety Considerations
High-Risk Populations Requiring Dose Adjustment or Avoidance
- Infants <2 years: Black box warning exists for similar sedatives due to fatal respiratory depression risk 1
- Hepatic impairment: Contraindicated - drug is metabolized by hepatocytes 4
- Renal impairment: Use with extreme caution - primarily eliminated by kidneys 4
- Elderly patients: May be more sensitive to usual adult doses 5; psychiatric indication for insomnia is no longer justified in this population 4
Factors Predicting Sedation Failure
Higher failure rates occur with 7:
- Heavier weight patients
- History of previous sedation or sedation failure
- MRI procedures or multiple simultaneous procedures
- Standard or reduced doses (<40 mg/kg)
Better success rates with:
- Outpatients
- Hearing screening procedures
- Sleep-deprived patients
Contraindications
- Gastric ulcers
- Hepatic insufficiency
- Porphyria
- Respiratory insufficiency
- Concurrent anticoagulant use
- Hypersensitivity 4
Route-Specific Considerations
Intravenous Administration
This route is not recommended and lacks proper documentation 8. Two accidental IV cases resulted in CNS depression with minimal local effects, but this represents off-label use without established safety data.
Oral vs Rectal
- Oral: 91% success rate but 20% vomiting rate 2
- Rectal: 84% success rate with 0% vomiting, 4.5% diarrhea 2
Toxicity and Overdose Management
Cardiovascular Toxicity
- Doses of 219 mg/kg caused transient bigeminy
- Doses up to 960 mg/kg caused torsades de pointes and ventricular fibrillation 8
- Treatment: Beta blockers are effective for arrhythmias; defibrillation for ventricular fibrillation 8
Common Adverse Events
- Intraoperative: Respiratory problems (hypoxia, apnea) - usually temporary 9
- Postoperative: Prolonged sedation, vomiting (4.3%), hyperactivity (<2%), respiratory symptoms (<2%) 3, 9
- Serious complications: 12 deaths reported in dental sedation literature, primarily from dosing errors and polypharmacy 9
Monitoring Requirements
Per AAP guidelines, all chloral hydrate sedation requires 1:
- Immediate availability of age-appropriate resuscitation equipment
- Continuous monitoring capability
- Personnel trained in airway management
- Emergency cart with bag-valve-mask, airways, laryngoscope, etc.
- Protocol for EMS activation in non-hospital settings
Current Status and Recommendations
The liquid formulation is no longer commercially available in many regions; hospital pharmacies now compound their own formulations 1. Recent stability data shows compounded chloral hydrate in PCCA SuspendIt remains stable for 180 days at concentrations of 25-100 mg/mL 10.
Given concerns about genotoxicity, carcinogenicity, and unpredictable responses, chloral hydrate should be reserved for single-use pediatric procedural sedation only, not for chronic insomnia management 4, 9.